COVID-19 vaccine: Novavax initiates Phase 1/2 Clinical Trial
by Press Release from Outbreak News Today on (#53YHN)
Biotechnology company, Novavax, Inc. today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVXCoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVXCoV2373 includes Novavax' proprietary MatrixMTM adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Preliminary immunogenicity and safety results [...]
The post COVID-19 vaccine: Novavax initiates Phase 1/2 Clinical Trial appeared first on Outbreak News Today.